Free Trial
→ I'm giving you a space stock today. Free. (From Behind the Markets) (Ad)tc pixel Free CLVR Stock Alerts

Clever Leaves (CLVR) Competitors

Clever Leaves logo
$0.01 0.00 (0.00%)
As of 10/13/2026 01:03 PM Eastern
Compare

CLVR vs. SXTPW, BFRIW, CALA, CINGW, and CMRAW

Should you buy Clever Leaves stock or one of its competitors? Clever Leaves's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Clever Leaves compare to 60 Degrees Pharmaceuticals?

Clever Leaves (NASDAQ:CLVR) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Clever Leaves. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Clever Leaves. 60 Degrees Pharmaceuticals' average media sentiment score of 1.19 beat Clever Leaves' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Clever Leaves Neutral
60 Degrees Pharmaceuticals Positive

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$7.56N/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Clever Leaves beats 60 Degrees Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Biofrontera has higher revenue and earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$7.56N/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Biofrontera had 2 more articles in the media than Clever Leaves. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Clever Leaves. Biofrontera's average media sentiment score of 0.91 beat Clever Leaves' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Positive
Clever Leaves Neutral

Summary

Biofrontera beats Clever Leaves on 3 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Calithera Biosciences?

Clever Leaves (NASDAQ:CLVR) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Clever Leaves has a beta of 3892.08, indicating that its share price is 389,108% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.52, indicating that its share price is 252% less volatile than the broader market.

Clever Leaves has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$7.56N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

In the previous week, Calithera Biosciences had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Clever Leaves. Calithera Biosciences' average media sentiment score of 0.67 beat Clever Leaves' score of 0.00 indicating that Calithera Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Clever Leaves Neutral
Calithera Biosciences Positive

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Clever Leaves beats Calithera Biosciences on 5 of the 8 factors compared between the two stocks.

How does Clever Leaves compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cingulate had 2 more articles in the media than Clever Leaves. MarketBeat recorded 2 mentions for Cingulate and 0 mentions for Clever Leaves. Cingulate's average media sentiment score of 1.41 beat Clever Leaves' score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Positive
Clever Leaves Neutral

Cingulate has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$7.56N/A

Summary

Clever Leaves beats Cingulate on 3 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Comera Life Sciences?

Clever Leaves (NASDAQ:CLVR) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Comera Life Sciences has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$7.56N/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Comera Life Sciences Neutral

Summary

Clever Leaves beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLVR vs. The Competition

Export
MetricClever LeavesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$20K$12.37B$7.28B$12.92B
Dividend YieldN/A2.63%2.51%22.89%
P/E Ratio0.00805.17275.2825.28
Price / Sales0.00746.04562.3878.55
Price / CashN/A86.6577.1653.04
Price / Book0.009.1810.525.92
Net Income-$17.90M$2.82B$3.50B$381.04M
7 Day PerformanceN/A-4.50%-4.32%-4.41%
1 Month PerformanceN/A-8.55%-8.66%-7.30%
1 Year PerformanceN/A-6.35%1.94%-5.04%

Clever Leaves Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLVR
Clever Leaves
N/A$0.01
flat		N/AN/A$20K$17.42MN/A296
SXTPW
60 Degrees Pharmaceuticals
N/A$0.02
+4.2%		N/A-42.9%$0.00$1.11MN/A3
BFRIW
Biofrontera
N/A$0.01
flat		N/A-94.2%$0.00$46.18MN/A94
CALA
Calithera Biosciences
N/A$0.00
flat		N/A-50.0%$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
flat		N/A-91.5%$0.00N/AN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...
Behind the Markets | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel